Whitty, CJ; Chiodini, PL; Laloo, DG; (2013) Investigation and treatment of imported malaria in non-endemic countries. BMJ (Clinical research ed), 346. f2900. ISSN 0959-8138 DOI: https://doi.org/10.1136/bmj.f2900

Downloaded from: http://researchonline.lshtm.ac.uk/1035382/

DOI: https://doi.org/10.1136/bmj.f2900

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Creative Commons Attribution Non-commercial http://creativecommons.org/licenses/by-nc/3.0/
Investigation and treatment of imported malaria in non-endemic countries

Christopher J M Whitty consultant physician and professor of international health, Peter L Chiodini consultant parasitologist, David G Lalloo professor of tropical medicine

1 Hospital for Tropical Diseases, London WC1E 6JB, UK; 2 PHE Malaria Reference Laboratory, London School of Hygiene and Tropical Medicine, London, UK; 3 Liverpool School of Tropical Medicine, Liverpool, UK

Every year, several thousand people with malaria arrive in non-endemic countries, and about 1600 arrive in the United Kingdom alone. Case fatality in the UK, as elsewhere, is around 1% overall but varies by age and previous exposure to malaria. This rate is similar to that seen in endemic countries, but the age profile of deaths is very different. In Africa mortality is highest in young children, but in imported cases it is highest in older patients, especially those over 65 years. If malaria is treated early, with widely available drugs before it becomes severe, death is avoidable and a full recovery almost guaranteed. Late presentation carries a higher risk of death. The management of severe malaria is a medical emergency. This review describes how to recognise and diagnose malaria, the current treatment of uncomplicated malaria, and the management of patients with severe disease. It concentrates on adults and recent advances relevant to non-endemic high resource countries such as Europe and North America. Different challenges arise in low resource endemic settings and are not covered in this review.

What is malaria?

Malaria is a tropical parasitic disease of red blood cells transmitted by anopheles mosquitoes. Five species affect humans. The most serious, and in Europe the most common, imported form is Plasmodium falciparum malaria, which causes most deaths from imported malaria. The other common imported form is P vivax malaria. It is generally less severe but can recur several months after treatment owing to relapse from hypnozoites (“sleeping” parasites) in the liver. P ovale malaria is similar to P vivax malaria, as is P malariae malaria although it does not relapse. P knowlesi is a monkey malaria parasite that has recently been recognised to infect humans and is rare in imported cases.

Who is at risk of acquiring and dying from malaria?

Several countries that are frequented by tourists and people visiting friends and relatives have regions where the average person gets clinical malaria four or more times a year. Observational study found that around one in five travellers with a history of fever returning from sub-Saharan Africa had malaria. Rates are much lower (maybe 1/100) in unwell travellers returning from malaria endemic Asia and Latin America, although the risk of malaria varies widely in these continents. Failure to take effective prophylaxis is associated with acquiring malaria in several observational studies. Travellers whose families emigrated from malaria endemic countries, and who are visiting friends and relatives, are at particularly high risk of acquiring malaria, especially those of west African heritage. People who travelled to visit friends and relatives account for around 65% of all malaria cases in the UK, and their reported chemoprophylaxis use is lower than for other travellers. Vivax malaria, the form of malaria most commonly imported from Asia and Latin America, had been declining over the past two decades in the UK. Observational studies of imported febrile illnesses in travellers have shown that malaria remains one of the most common potentially life threatening causes of fever in travellers. Such studies also show that increasing age, delay to diagnosis, and presenting in an area where malaria is seldom seen or treated increase the risk of dying from falciparum malaria once acquired (evidence from the UK only). Although in Africa most deaths are in children, in non-endemic high resource settings observational studies show that older people have the greatest risk of dying from malaria if acquired, with minimal risk in children and young adults and a steadily increasing risk over the age range; case fatality in those over 65 years is 4.6% in the UK.
How to recognise malaria in adults

The symptoms and signs of malaria are non-specific and overlap with many other common infections. Influenza is a common misdiagnosis, and case reports show that malaria has also been misdiagnosed as gastroenteritis, hepatitis, and lower respiratory tract infection.10 The key to diagnosing malaria is to take a travel history for all patients and request a malaria test in anyone who feels unwell and has recently been to an endemic country. A history of fever will be present in most patients with malaria, but around half will have no fever at the time of presentation; absence of fever cannot exclude disease.1 Headache, malaise, and rigors are common symptoms but not invariable. Certain symptoms and signs of severe or potentially complicated malaria—such as jaundice, seizures, or rapid breathing—can result in the misdiagnosis of malaria—for example, as hepatitis (table 1). It is therefore essential to exclude malaria with a thick and thin blood film rather than rely on clinical diagnosis based on symptoms; attempts to produce algorithms that reliably predict malaria on the basis of symptoms have been unsuccessful.11 In patients returning from malaria endemic countries, any symptom or sign compatible with an infection should raise the possibility of malaria. Although most cases of falciparum malaria present within three months of return, case reports and Public Health England data show that some cases in travellers present up to a year after return, and many cases of non-falciparum malaria occur over a year later.12

How is malaria diagnosed?

The gold standard for malaria diagnosis in clinical practice remains microscopic examination of a blood film. Good rapid diagnostic tests for falciparum malaria with sensitivity and specificity above 97%, and fairly good ones for non-falciparum malaria,13 are now widely available to hospitals in Europe. Most, however, are not as sensitive as an experienced microscopist and give no information about parasite density, which is important for prognosis and treatment decisions. Therefore these rapid tests should be seen as an adjunct to, rather than an alternative to, conventional microscopic diagnosis, and their sole use is not recommended. Newer polymerase chain reaction based diagnostic methods are currently used only in research settings, although they will probably become clinically useful in non-endemic settings within the next decade, especially to detect mixed infections and potentially drug resistant cases.14

What are the indicators of severe or complicated disease in adults?

Once malaria is diagnosed, the priority is to determine the severity of disease because this determines treatment. Table 1 shows modified World Health Organization indicators of severe disease; patients with any one of these will need parenteral treatment with antimalarial drugs. HIV positive patients have an increased risk of severe malaria and of drug interactions.15 Observational studies have shown that three severe syndromes predominate in adults: cerebral malaria—in practice, malaria with reduced level of consciousness, neurological signs, or seizures; renal failure; and acute lung injury (or acute respiratory distress syndrome).16 Disseminated intravascular coagulation and shock are less common and seldom occur in isolation. In addition, jaundice (due to recent major haemolysis) or a parasite count in the blood of greater than 2%, even if the patient does not appear clinically unwell, is a sign that severe malaria is more likely to develop.

What are the indicators of severe or complicated disease in children?

Multicentre observational studies, mainly from Africa, have shown that anaemia, raised respiratory rate due to acidosis (rather than lung injury), and cerebral malaria are the most common signs of severity in young children, although this pattern varies by age, with cerebral malaria becoming more common in older children.17

What about malaria in pregnancy?

Treatment of pregnant women as having potentially complicated malaria, although not all will need parenteral treatment. The risks associated with severe disease are greater than in non-pregnant women, and there are serious risks to the pregnancy, including miscarriage, in otherwise non-severe disease.18 The management of malaria in pregnancy has particular challenges,19 because of the risks the disease poses to the pregnancy and because the theoretical risks of teratogenicity of antimalarial drugs need to be balanced with the substantial risks of undertreating; specialist advice is strongly recommended. Data from animals suggest that artemisinin drugs are teratogenic in early pregnancy, but human data are reassuring, with no current evidence of increased risk.20 Hypoglycaemia is a problem in pregnant women with malaria,21 and any pregnant woman with a reduced level of consciousness should be given glucose while awaiting blood glucose measurements.
How is uncomplicated non-falciparum malaria managed?

Several case reports indicate that vivax malaria, and possibly ovale and malariae malaria, cause severe disease more often than was once thought, and their label as "benign" malaria is misleading. However, patients with non-falciparum malaria need to be admitted only if they have indicators of severe disease (table 1) or cannot take oral drugs. Provided the laboratory making the diagnosis is experienced and unlikely to have mistaken falciparum or rare mixed species infection (<1%), chloroquine remains the drug of choice to treat vivax, ovale, and malariae malaria. There is limited but growing chloroquine resistance in vivax in eastern Asia and the Pacific. Evidence from clinical trials and a systematic review shows that most patients with vivax malaria, even those from South Asia or East Asia, respond to chloroquine within three days (see table 2 for dosing). Good evidence from clinical trials shows that artemisinin combination treatment (ACT) or quinine both work against vivax malaria at the same doses as those used for falciparum malaria (see below) if there is uncertainty about species or in patients with mixed infections.

The biggest difficulty in managing patients with vivax or ovale malaria is that they can relapse several times after an initial episode, often more than a year after initial infection. Chloroquine and ACT treat the initial infection but do not kill the hypnozoites in the liver, which cause recurrent malaria. Primaquine is the only drug currently licensed to kill these hypnozoites and prevent or reduce the risk of relapse. Apart from the need for a two week course, primaquine has two disadvantages. Firstly, resistance is gradually spreading, particularly in Oceania and eastern Asia, so that higher doses are now needed. In the United States and UK, the current recommended dose for vivax malaria in adults is 30 mg a day for 14 days (15 mg a day for ovale). In addition, case reports and observational studies have found that treatment with primaquine in patients with phenotypic glucose-6-phosphate dehydrogenase (G6PD) deficiency can lead to haemolysis, which can be life threatening. G6DP deficiency therefore needs to be excluded before the drug is taken. G6PD deficiency can affect more than 10% of the population in malaria endemic countries, although its prevalence is lower in people with malaria. Patients should not take primaquine until their G6PD status is known, but treatment with chloroquine must not be delayed. Unfortunately, the only new anti-hypnozoite drug likely to be licensed in the next few years, tafenoquine, has similar risks with G6PD deficiency.

How should uncomplicated falciparum malaria be managed?

The severity of uncomplicated falciparum malaria is difficult to assess at presentation owing to the complex life cycle of the parasites, so all patients presenting with falciparum malaria in non-endemic countries should be admitted. Patients can seem well initially and then deteriorate despite treatment, and in around 20% of patients the parasite count rises in the first 24 hours despite adequate treatment. Do not assume that patients who once lived in endemic Africa reduces the risk of dying from malaria, admission to intensive care and death can still occur.

Provided oral treatments can be tolerated, parenteral treatment is not needed if there are no clinical or laboratory signs of severity (table 1). Because of a lack of evidence, guidelines vary about the threshold parasite count above which to give parenteral treatment in patients without symptoms or signs of severity: UK guidelines (designed for non-endemic countries) suggest parasite counts over 2%, whereas WHO suggests over 5%. Chloroquine resistance is near universal, so this drug should not be used. A variety of drug combinations are effective against uncomplicated falciparum malaria (table 2). Falciparum malaria should always be treated with a combination of at least two drugs. Commonly used options include ACTs, quinine combined with another drug, and atovaquone-proguanil. Most non-endemic countries have evidence based expert recommendations that are periodically updated on the basis of trends in epidemiology of imported malaria, emerging drug resistance, and local availability of drugs.

There is good evidence from large trials and systematic reviews that ACT or quinine based combinations will be effective in malaria from Africa, most of Asia, and Latin America; ACT drugs are generally better tolerated and reduce parasite counts more rapidly. Two ACTs, artemether-lumefantrine and dihydroartemisinin-piperaquine, are currently licensed in Europe and may become available in the US.

Is malaria resistance increasing?

P falciparum has developed resistance to several older antimalarials, and resistance continues to evolve. Several clinical studies show clear evidence of early emerging artemisinin resistance in South East Asia (Cambodia, Thailand, and parts of Burma), although ACTs still work clinically. Clinical trials have also noted partial quinine resistance in the same area. Several recent trials have found no evidence that quinine or artesunate resistance is a serious clinical problem outside these areas. Resistance to some older companion drugs (such as sulfadoxine-pyrimethamine) is widespread, but well conducted trials (in endemic countries) and observational data (in imported cases) show that the combinations in table 2 are effective for most (>95%) cases of imported malaria. Atovaquone-proguanil has been associated with occasional treatment failure in some case reports, so many centres do not use it as first line treatment; it should not be used in people who have been taking it prophylactically. Atovaquone-proguanil may be appropriate second line treatment for the rare cases of treatment failure with effective first line combinations, particularly those from South East Asia. Falciparum malaria does not relapse and patients can be reassured that they are unlikely to have recurrent malaria if they complete a full course of treatment. Any further attacks (generally within six weeks) usually represent treatment failure. Warn travellers about the growing problem of poor quality and counterfeit antimalarial drugs in many endemic countries.

How should severe and potentially complicated malaria be managed?

Severe malaria is a medical emergency, and the main priority is for patients to receive adequate doses of effective drugs as soon as possible. Quinine (quinidine in the US, which is broadly equivalent) or artesunate are the two drugs used for parenteral treatment of severe malaria. Clear evidence from large randomised trials now shows that although quinine remains effective, artesunate is associated with a survival advantage (relative risk reduction of 22-34%) in adults and children in Asia and Africa. Previously, the poor quality and limited availability of parenteral artesunate has been a problem in many non-endemic countries. However, although not licensed in
The outlook for adults who survive an initial episode of malaria can now be sourced (including through the Centers for Disease Control and Prevention in the US). Patients should always be started on parenteral quinine while trying to obtain artesunate if it is not initially available to avoid delay in effective treatment. In adults, artesunate confers the greatest survival benefit in those with very high parasite counts (>10%).

Renal failure and lung injury

Renaal failure and lung injury are both rare in children, particularly those with very high parasite counts (>10%).

PLC is supported by the UCL Hospitals Comprehensive Biomedical Research Centre Infection Theme.

Contributions: All authors contributed to the writing of this paper. GMC is guarantor.

Competing interests: We have read and understood the BMJ Group policy on declaration of interests and declare the following interests: None.

Provenance and peer review: Commissioned; externally peer reviewed.

References

Additional educational resources

Resources for healthcare professionals


Resources for patients


Advisory Committee on Prevention of Malaria in UK. www.hpa.org.uk/infections/topics_az/malaria/guidelines.htm. Travellers’ handbook

Cite this as: BMJ 2013;346:f2900 © BMJ Publishing Group Ltd 2013
## Tables

### Table 1 | WHO criteria for severe malaria, modified for non-endemic high resource settings (any one indicates potentially severe disease)*

<table>
<thead>
<tr>
<th>Symptoms, signs, and laboratory indicators of severe disease</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced level of consciousness</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Seizures</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Respiratory distress</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Severe anaemia (haemoglobin &lt;70 g/L)*</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td>Hypoglycaemia†</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Renal failure</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Hyperparasitaemia (&gt;10% red cells parasitised)</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Disseminated intravascular coagulation</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Shock</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Warning signs of potentially complicated malaria (requires parenteral treatment):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jaundice</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Parasite count &gt;2%</td>
<td>+++</td>
<td>+</td>
</tr>
</tbody>
</table>

*+=rare; +++=uncommon; +++=common (definition depends on age, state of immunity, and other factors).
†Common in pregnant women.
**Table 2** Common licensed drugs, drug combinations, and drug doses for malaria

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose in adults</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uncomplicated vivax, ovale, and malariae malaria</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloroquine</td>
<td>620 mg base, then 310 mg base at 6, 24, and 48 hours</td>
<td>Test for G6PD deficiency before patients take it</td>
</tr>
<tr>
<td>Primaquine (after chloroquine)</td>
<td>30 mg per day for 14 days</td>
<td></td>
</tr>
<tr>
<td><strong>Uncomplicated falciparum malaria</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artemether-lumefantrine</td>
<td>4 tablets (adult) initially, followed by 5 further doses of 4 tablets at 8, 24, 36, 48, and 60 hours</td>
<td></td>
</tr>
<tr>
<td>Quinine combinations</td>
<td>600 mg every 8 hours for 7 days or until parasites have cleared</td>
<td>Follow with clindamycin for 7 days, doxycycline for 7 days, or sulfaadoxine-pyrimethamine once; ringing in ears a common side effect</td>
</tr>
<tr>
<td>Atovaquone-proguanil</td>
<td>4 tablets once a day for 3 days</td>
<td>Avoid if patients were on atovaquone-proguanil prophylaxis</td>
</tr>
<tr>
<td><strong>Severe or potentially complicated malaria</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quinine</td>
<td>20 mg/kg quinine intravenously, followed by 10 mg/kg 8-12 hourly until parasites have cleared</td>
<td>By slow infusion over 4 hours; hypoglycaemia and arrhythmias are side effects</td>
</tr>
<tr>
<td>Artesunate</td>
<td>2.4 mg/kg intravenously, followed by 2.4 mg/kg at 12 hours, then 2.4 mg/kg daily until parasites have cleared</td>
<td>As a bolus over 5 minutes</td>
</tr>
</tbody>
</table>

G6PD=glucose-6-phosphate dehydrogenase.